Novavax | NVAX - Заемный капитал





Заемный капитал Изменить Дата
Adma Biologics USD 69.33M 750K 2025-12
Agenus USD 169.66M 146.06M 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Cassava Sciences USD 0 0 2024-12
Geron USD 119.55M 283K 2025-12
GlaxoSmithKline GBP 14.71B 186M 2025-12
MannKind USD 548.44M 244.79M 2025-12
Merck USD 39.97B 6B 2025-09
Minerva Neurosciences USD 0 86.58M 2024-09
Moderna USD 610M 584M 2025-12
Novartis USD 29.59B 5.35B 2025-12
Novavax USD 246.3M 200K 2025-12
Pfizer USD 57.41B 93M 2025-09
Sanofi EUR 15.72B 2.45B 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
TG Therapeutics USD 245.64M 305K 2025-12